Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Director departure
Appointed director
CC transcript
X4 Pharmaceuticals, Inc (XFOR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/25/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from"
08/03/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
06/30/2023 144 Form 144 - Report of proposed sale of securities:
06/30/2023 144 Form 144 - Report of proposed sale of securities:
06/16/2023 SC 13G MILLENNIUM MANAGEMENT LLC reports a 5.2% stake in X4 PHARMACEUTICALS, INC.
06/09/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
06/01/2023 D Form D - Notice of Exempt Offering of Securities:
06/01/2023 8-K Regulation FD Disclosure  Interactive Data
05/31/2023 144 Form 144 - Report of proposed sale of securities:
05/26/2023 SC 13D/A Growth Equity Opportunities 18 VGE, LLC reports a 10% stake in X4 Pharmaceuticals, Inc.
05/16/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events ...
Docs: "X4 PHARMACEUTICALS, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK",
"SECURITIES PURCHASE AGREEMENT",
"REGISTRATION RIGHTS AGREEMENT",
"X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market",
"X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome",
"01 02 03 04 05 06"
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
05/04/2023 8-K Quarterly results
05/04/2023 8-K Quarterly results
Docs: "X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update"
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/25/2023 ARS Form ARS - Annual Report to Security Holders:
04/25/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/25/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/21/2023 8-K Regulation FD Disclosure  Interactive Data
03/21/2023 8-K Quarterly results
Docs: "X4 Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update"
03/10/2023 8-K Other Events  Interactive Data
02/14/2023 SC 13G/A ORBIMED ADVISORS LLC reports a 8.2% stake in X4 PHARMACEUTICALS, INC.
02/14/2023 SC 13G/A Ikarian Capital, LLC reports a 0.3% stake in X4 PHARMACEUTICALS, INC.
02/14/2023 SC 13G/A Bain Capital Life Sciences Fund, L.P. has filed a Schedule 13D for X4 Pharmaceuticals, Inc.
01/20/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
01/13/2023 SC 13G Empery Asset Management, LP reports a 5.1% stake in X4 Pharmaceuticals, Inc.
01/06/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
01/05/2023 8-K Regulation FD Disclosure  Interactive Data
12/23/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "X4 Pharmaceuticals, Inc. Amended and Restated 2019 Inducement Equity Incentive Plan",
"X4 Pharmaceuticals, Inc. Amended and Restated 2019 Inducement Equity Incentive Plan"
12/19/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
12/09/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy